CY1121660T1 - Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων - Google Patents
Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεωνInfo
- Publication number
- CY1121660T1 CY1121660T1 CY20191100564T CY191100564T CY1121660T1 CY 1121660 T1 CY1121660 T1 CY 1121660T1 CY 20191100564 T CY20191100564 T CY 20191100564T CY 191100564 T CY191100564 T CY 191100564T CY 1121660 T1 CY1121660 T1 CY 1121660T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- pharmaceutical composition
- hiv infections
- hiv
- ingredients
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000031886 HIV Infections Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Η εφεύρεση σχετίζεται με το πεδίο της χημικής και φαρμακευτικής βιομηχανίας, ειδικά με μια φαρμακευτική σύνθεση για την θεραπεία μιας λοίμωξης από HIV• περιέχει τουλάχιστον έναν αναστολέα της πρωτεάσης του ΗIV ως δραστικό συστατικό, καθώς και φαρμακευτικά αποδεκτά έκδοχα με συγκεκριμένη ποσοτική αναλογία των συστατικών. Επιπλέον, η εφεύρεση ανήκει στη διαδικασία της παραγωγής της και σε μια μέθοδο θεραπείας. Η φαρμακευτική σύνθεση σύμφωνα με την εφεύρεση έχει αυξημένη βιοδιαθεσιμότητα και βελτιωμένες τεχνολογικές ιδιότητες σε σύγκριση με το πρωτότυπο φάρμακο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012158141/15A RU2505286C1 (ru) | 2012-12-29 | 2012-12-29 | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
PCT/RU2013/000817 WO2014104929A1 (ru) | 2012-12-29 | 2013-09-19 | Фармацевтическая композиция для лечения вич-инфекции |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121660T1 true CY1121660T1 (el) | 2020-07-31 |
Family
ID=49957619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100564T CY1121660T1 (el) | 2012-12-29 | 2019-05-29 | Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων |
Country Status (18)
Country | Link |
---|---|
US (1) | US10493034B2 (el) |
EP (1) | EP2939665B1 (el) |
CN (1) | CN104884050A (el) |
CA (1) | CA2896710C (el) |
CY (1) | CY1121660T1 (el) |
DK (1) | DK2939665T3 (el) |
EA (1) | EA029586B1 (el) |
ES (1) | ES2729568T3 (el) |
HR (1) | HRP20190882T1 (el) |
HU (1) | HUE043694T2 (el) |
LT (1) | LT2939665T (el) |
PL (1) | PL2939665T3 (el) |
PT (1) | PT2939665T (el) |
RS (1) | RS58837B1 (el) |
RU (1) | RU2505286C1 (el) |
SI (1) | SI2939665T1 (el) |
TR (1) | TR201908007T4 (el) |
WO (1) | WO2014104929A1 (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105194687A (zh) * | 2015-10-22 | 2015-12-30 | 浙江医药高等专科学校 | 沙喹那韦或其甲磺酸盐的环糊精包合物制备方法 |
WO2017086835A1 (ru) * | 2015-11-17 | 2017-05-26 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты) |
RU2616267C1 (ru) * | 2016-01-25 | 2017-04-13 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
PE20080422A1 (es) * | 2006-08-10 | 2008-04-28 | Cipla Ltd | Composicion solida antirretroviral de administracion oral |
PA8809601A1 (es) * | 2007-12-24 | 2009-07-23 | Cipla Ltd | Combinación anti-retroviral |
WO2009087410A2 (en) * | 2008-01-11 | 2009-07-16 | Cipla Limited | Solid pharmaceutical dosage form |
US8501961B2 (en) * | 2008-07-09 | 2013-08-06 | Purdue Research Foundation | HIV protease inhibitors and methods for using |
US20110034489A1 (en) * | 2009-07-31 | 2011-02-10 | Ranbaxy Laboratories Limited | Solid dosage forms of hiv protease inhibitors |
WO2012164575A2 (en) * | 2011-05-27 | 2012-12-06 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
EP2802354A4 (en) * | 2012-01-09 | 2015-07-29 | Virginia Tech Intell Prop | CELLULOSE DERIVATIVES FOR INHIBITING THE CRYSTALLIZATION OF MEDIALLY SOLUBLE DRUGS IN WATER |
EP2819668A4 (en) * | 2012-03-01 | 2015-07-29 | Hetero Research Foundation | COMPOSITIONS OF RITONAVIR |
WO2014184553A1 (en) * | 2013-05-15 | 2014-11-20 | Cipla Limited | Pharmaceutical antiretroviral compositions |
-
2012
- 2012-12-29 RU RU2012158141/15A patent/RU2505286C1/ru active
-
2013
- 2013-09-19 CN CN201380068729.6A patent/CN104884050A/zh active Pending
- 2013-09-19 SI SI201331474T patent/SI2939665T1/sl unknown
- 2013-09-19 EP EP13867546.7A patent/EP2939665B1/en active Active
- 2013-09-19 PT PT13867546T patent/PT2939665T/pt unknown
- 2013-09-19 RS RS20190656A patent/RS58837B1/sr unknown
- 2013-09-19 HU HUE13867546A patent/HUE043694T2/hu unknown
- 2013-09-19 TR TR2019/08007T patent/TR201908007T4/tr unknown
- 2013-09-19 LT LTEP13867546.7T patent/LT2939665T/lt unknown
- 2013-09-19 DK DK13867546.7T patent/DK2939665T3/da active
- 2013-09-19 ES ES13867546T patent/ES2729568T3/es active Active
- 2013-09-19 CA CA2896710A patent/CA2896710C/en not_active Expired - Fee Related
- 2013-09-19 WO PCT/RU2013/000817 patent/WO2014104929A1/ru active Application Filing
- 2013-09-19 EA EA201500710A patent/EA029586B1/ru unknown
- 2013-09-19 PL PL13867546T patent/PL2939665T3/pl unknown
-
2015
- 2015-06-29 US US14/753,395 patent/US10493034B2/en not_active Expired - Fee Related
-
2019
- 2019-05-14 HR HRP20190882TT patent/HRP20190882T1/hr unknown
- 2019-05-29 CY CY20191100564T patent/CY1121660T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20190882T1 (hr) | 2019-09-20 |
ES2729568T3 (es) | 2019-11-04 |
PL2939665T3 (pl) | 2020-01-31 |
WO2014104929A1 (ru) | 2014-07-03 |
CA2896710C (en) | 2019-03-26 |
DK2939665T3 (da) | 2019-06-11 |
EP2939665B1 (en) | 2019-03-20 |
CA2896710A1 (en) | 2014-07-03 |
HUE043694T2 (hu) | 2019-09-30 |
US20150297526A1 (en) | 2015-10-22 |
EP2939665A1 (en) | 2015-11-04 |
US10493034B2 (en) | 2019-12-03 |
RU2505286C1 (ru) | 2014-01-27 |
PT2939665T (pt) | 2019-06-14 |
CN104884050A (zh) | 2015-09-02 |
EP2939665A4 (en) | 2016-06-01 |
EA201500710A1 (ru) | 2015-10-30 |
RS58837B1 (sr) | 2019-07-31 |
LT2939665T (lt) | 2019-07-25 |
EA029586B1 (ru) | 2018-04-30 |
SI2939665T1 (sl) | 2019-08-30 |
TR201908007T4 (tr) | 2019-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118661T1 (el) | Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων | |
EA201892838A1 (ru) | Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их | |
EA201890124A1 (ru) | Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
EA201890123A1 (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
CY1121660T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων | |
CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
EA201892173A1 (ru) | Фармацевтический состав палбоциклиба и способ его получения | |
EA201401292A3 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
EA201590862A1 (ru) | Фармацевтические композиции | |
CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
PE20140255A1 (es) | Tableta dispersable en forma oral | |
TR201821116A2 (tr) | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ | |
IN2013MU03583A (el) | ||
CY1124782T1 (el) | Φαρμακοτεχνικες μορφες μακρας δρασης | |
IN2014MN02236A (el) | ||
IN2013MU00711A (el) | ||
BR112017000898A2 (pt) | oritavancina de alta pureza e método de produção da mesma | |
EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
BR112017024727A2 (pt) | cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal | |
EA201691490A1 (ru) | Фармацевтическая композиция, содержащая бринзоламид | |
EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA201890906A1 (ru) | ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης |